- Report
- March 2024
- 196 Pages
Global
From €3205EUR$3,374USD£2,749GBP
€3562EUR$3,749USD£3,054GBP
- Report
- October 2023
- 157 Pages
Global
From €5225EUR$5,500USD£4,481GBP
- Report
- May 2024
- 183 Pages
Global
From €3205EUR$3,374USD£2,749GBP
€3562EUR$3,749USD£3,054GBP
- Report
- February 2024
- 175 Pages
Global
From €4750EUR$5,000USD£4,073GBP
- Report
- February 2024
- 175 Pages
Global
From €4750EUR$5,000USD£4,073GBP
- Report
- February 2024
- 175 Pages
Global
From €4750EUR$5,000USD£4,073GBP
- Report
- January 2024
- 175 Pages
Global
From €4750EUR$5,000USD£4,073GBP
- Report
- January 2024
- 200 Pages
Global
From €4750EUR$5,000USD£4,073GBP
- Clinical Trials
- April 2024
- 180 Pages
Global
From €2375EUR$2,500USD£2,037GBP
- Clinical Trials
- April 2024
- 210 Pages
Global
From €2375EUR$2,500USD£2,037GBP
- Clinical Trials
- April 2024
- 130 Pages
Global
From €1900EUR$2,000USD£1,629GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1188EUR$1,250USD£1,018GBP
- Report
- May 2024
- 190 Pages
From €3205EUR$3,374USD£2,749GBP
€3562EUR$3,749USD£3,054GBP
- Report
- May 2024
- 136 Pages
From €6174EUR$6,499USD£5,294GBP
- Report
- December 2022
- 115 Pages
Global
From €4655EUR$4,900USD£3,992GBP
- Report
- August 2022
- 110 Pages
Global
From €4513EUR$4,750USD£3,870GBP
- Report
- April 2023
- 224 Pages
Global
From €7125EUR$7,500USD£6,110GBP
- Report
- April 2023
- 112 Pages
Global
From €3753EUR$3,950USD£3,218GBP
- Report
- August 2022
- 117 Pages
Global
From €4275EUR$4,500USD£3,666GBP
- Report
- August 2019
- 30 Pages
China
From €2090EUR$2,200USD£1,792GBP
Thrombolytics are a class of cardiovascular drugs used to treat acute ischemic stroke, myocardial infarction, and pulmonary embolism. They work by breaking down the clot that is blocking the blood vessel, allowing blood to flow freely. Thrombolytics are typically administered intravenously, and can be used in combination with other treatments such as anticoagulants and antiplatelet drugs. The most commonly used thrombolytic is tissue plasminogen activator (tPA), which is a recombinant form of the naturally occurring enzyme plasminogen.
The thrombolytics market is highly competitive, with a number of companies offering products for the treatment of cardiovascular diseases. Some of the major players in the market include Boehringer Ingelheim, Pfizer, Sanofi, Bristol-Myers Squibb, and Merck. Show Less Read more